Respirerx Pharmaceuticals Inc., of Gen Rock, N.J., said it reached agreement with the Medications Development Program of the National Institute of Drug Abuse (NIDA) to conduct research on its compounds CX717 and CX1739. NIDA will evaluate the company's ampakine compounds in a series of preclinical pharmacologic, pharmacokinetic and toxicologic protocols to determine their potential effectiveness for the treatment of drug abuse and addiction.